BEIJING (Global Times) — The world’s first aerosolized inhalable adenovirus type-5 vector-based Covid-19 vaccine (Ad5-nCoV) is progressing well toward obtaining emergency-use approval, and is expected to be in wide use soon thereafter, the Global Times learned from the vaccine developer and an industry insider on Wednesday.
Aerosolized inhalable Ad5-nCoV can produce a strong cellular immune response, which maintains the same level as that obtained by traditional intramuscular injections in 14 days.
Besides, the increase of antibodies after inhaling Ad5-nCoV as a booster shot could be seven to eight times that of an inactivated vaccine as a booster, the Global Times learned from the developer CanSinoBIO.
The vaccine was jointly developed by with researchers from the Institute of Military Medicine under the Academy of Military Sciences led by Chen Wei. Further clinical trials are ongoing.
Experts recommend the inhaled vaccine as a promising candidate for booster shots of inactivated vaccines.
The phase I clinical trials found that an aerosolized booster vaccination taken 28 days after the first intramuscular injection “induced strong IgG and neutralizing antibody responses,” said the report of the trial, which was published in The Lancet Infectious Diseases on Monday.
The trial also showed that two doses of the aerosol form of Ad5-nCoV were well tolerated, without causing any vaccine-related serious adverse events.